Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Focal Dermal Hypoplasia (FDH)”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Not applicableActive Not RecruitingNCT00691223
What this trial is testing

Study of Selected X-linked Disorders: Goltz Syndrome

Who this might be right for
Focal Dermal Hypoplasia (FDH)Goltz Syndrome
Baylor College of Medicine 84
Early research (Phase 1)Study completedNCT05134727
What this trial is testing

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Who this might be right for
Idiopathic Pulmonary Fibrosis
AstraZeneca 63
Large-scale testing (Phase 3)WithdrawnNCT03070691
What this trial is testing

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Who this might be right for
Basal Cell Carcinoma
Novartis Pharmaceuticals
Not applicableStudy completedNCT02463656
What this trial is testing

Growth Arrest in Focal Dermal Hypoplasia

Who this might be right for
Focal Dermal Hypoplasia
University of Colorado, Denver 16
Testing effectiveness (Phase 2)Study completedNCT00961896
What this trial is testing

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Who this might be right for
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT01350115
What this trial is testing

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Who this might be right for
Basal Cell CarcinomaGorlin SyndromeNevoid Basal Cell Carcinoma Syndrome
Novartis Pharmaceuticals 10